Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Total Debt (2016 - 2019)

Bone Biologics has reported Total Debt over the past 3 years, most recently at $8.2 million for Q4 2017.

  • Quarterly Total Debt fell 6.09% to $8.2 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2017, down 6.09% year-over-year, with the annual reading at $8.2 million for FY2017, 6.09% down from the prior year.
  • Total Debt was $8.2 million for Q4 2017 at Bone Biologics, down from $20.1 million in the prior quarter.
  • Over five years, Total Debt peaked at $20.1 million in Q3 2017 and troughed at $7.1 million in Q4 2015.
  • The 3-year median for Total Debt is $14.6 million (2016), against an average of $14.0 million.
  • The largest YoY upside for Total Debt was 34.34% in 2017 against a maximum downside of 6.09% in 2017.
  • A 3-year view of Total Debt shows it stood at $7.1 million in 2015, then rose by 23.72% to $8.8 million in 2016, then fell by 6.09% to $8.2 million in 2017.
  • Per Business Quant, the three most recent readings for BBLG's Total Debt are $8.2 million (Q4 2017), $20.1 million (Q3 2017), and $19.1 million (Q2 2017).